Rouillon, Frédéric

Agomelatine Prevents Relapse in Patients With Major Depressive Disorder Without Evidence of a Discontinuation Syndrome: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial

Goodwin, G. M., Emsley, R., Rembry, S., Rouillon, F., & the Agomelatine Study Group (2009) · The Journal of Clinical Psychiatry

Treatment of Major DepressionBipolar Disorder and Treatment

Cited by 340

Mortality in schizophrenia.

Auquier, P., Lançon, C., Rouillon, F., Lader, M., & Holmes, C. (2006) · Pharmacoepidemiology and Drug Safety

Schizophrenia research and treatmentSuicide and Self-Harm Studies

Cited by 249

Psychological distress in first year university students: socioeconomic and academic stressors, mastery and social support in young men and women

Verger, P., Combes, J.-B., Kovess-Masfety, V., Choquet, M., Guagliardo, V., Rouillon, F., & Peretti-Wattel, P. (2009) · Social Psychiatry and Psychiatric Epidemiology

Student Stress and CopingHealthcare professionals’ stress and burnout

Cited by 235

Psychiatric disorders in students in six French universities: 12-month prevalence, comorbidity, impairment and help-seeking

Verger, P., Guagliardo, V., Gilbert, F., Rouillon, F., & Kovess-Masfety, V. (2010) · Social Psychiatry and Psychiatric Epidemiology

Mental Health Treatment and AccessStudent Stress and Coping

Cited by 178

Cancer mortality in patients with schizophrenia: An 11‐year prospective cohort study

Tran, E., Rouillon, F., Loze, J., Casadebaig, F., Philippe, A., Vitry, F., & Limosin, F. (2009) · Cancer

Schizophrenia research and treatmentGlobal Cancer Incidence and Screening

Cited by 173

Assessing and interpreting personality change and continuity in patients treated for major depression.

De Fruyt, F., Van Leeuwen, K., Bagby, R. M., Rolland, J.-P., & Rouillon, F. (2006) · Psychological Assessment

Personality Traits and PsychologyPersonality Disorders and Psychopathology

Cited by 168

Milnacipran efficacy in the prevention of recurrent depression: a 12-month placebo-controlled study

Rouillon, F., Warner, B., Pezous, N., & Bisserbe, J. C. (2000) · International Clinical Psychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 47

Efficacité du « débriefing psychologique » dans la prévention des troubles psychologiques post-traumatiques

Aulagnier, M., Verger, P., & Rouillon, F. (2004) · Revue d'Épidémiologie et de Santé Publique

Posttraumatic Stress Disorder ResearchMigration, Health and Trauma

Cited by 28

L’alcool en France et ses conséquences médicales et sociales : regard de l’entourage et des médecins généralistes

Hoertel, N., Crochard, A., Rouillon, F., & Limosin, F. (2014) · L'Encéphale

Substance Abuse Treatment and OutcomesAlcohol Consumption and Health Effects

Cited by 24

Strategies of Treatment With Olanzapine in Schizophrenic Patients During Stable Phase: Results of a Pilot Study

Rouillon, F., Chartier, F., & Gasquet, I. (2008) · European Neuropsychopharmacology

Schizophrenia research and treatmentPsychiatric care and mental health services

Cited by 23

Is it time to shift to better characterization of patients in trials assessing novel antidepressants? An example of two relapse prevention studies with agomelatine

Goodwin, G. M., Boyer, P., Emsley, R., Rouillon, F., & de Bodinat, C. (2013) · International Clinical Psychopharmacology

Treatment of Major DepressionAnxiety, Depression, Psychometrics, Treatment, Cognitive Processes

Cited by 20